SCHG vs XBI
Schwab US Large-Cap Growth ETF vs SPDR S&P Biotech ETF
- • SCHG has the lower expense ratio at 0.04% vs 0.35% for XBI.
- • SCHG pays a higher dividend yield (0.39%).
Side-by-side metrics
| Metric | SCHG | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.04% | 0.35% |
Dividend yield Trailing 12-month yield. | 0.39% | 0.36% |
AUM Assets under management — bigger funds are typically more liquid. | $59.07B | $10.73B |
YTD return | 5.17% | 33.79% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.21 | 1.10 |
P/E ratio | 32.30 | — |
Last price | $34.44 | $164.01 |
Inception | — | — |
Issuer | Schwab | State Street |
SCHG top holdings
| NVDA | NVIDIA Corp | 10.02% |
| AAPL | Apple Inc | 8.78% |
| MSFT | Microsoft Corp | 5.81% |
| AMZN | Amazon.com Inc | 4.99% |
| GOOGL | Alphabet Inc Class A | 4.40% |
| AVGO | Broadcom Inc | 3.74% |
| GOOG | Alphabet Inc Class C | 3.52% |
| LLY | Eli Lilly and Co | 3.31% |
| AMD | Advanced Micro Devices Inc | 2.89% |
| TSLA | Tesla Inc | 2.82% |
XBI top holdings
| APGE | Apogee Therapeutics Inc | 1.49% |
| MRNA | Moderna Inc | 1.41% |
| TWST | Twist Bioscience Corp | 1.41% |
| ORKA | Oruka Therapeutics Inc | 1.38% |
| KYMR | Kymera Therapeutics Inc Ordinary Shares | 1.36% |
| VKTX | Viking Therapeutics Inc | 1.30% |
| PRAX | Praxis Precision Medicines Inc Ordinary Shares | 1.29% |
| ERAS | Erasca Inc | 1.27% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.20% |
| RYTM | Rhythm Pharmaceuticals Inc | 1.20% |
About SCHG
SCHG (Schwab US Large-Cap Growth ETF) is Large-cap US growth at low cost. Managed by Schwab, the fund carries $59.1B in assets under management, an expense ratio of 0.04%, a dividend yield of 0.39%. Its largest holding is NVIDIA Corp (NVDA), which represents 10.0% of the portfolio. Real Estate is the fund's largest sector exposure at 0.6%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.7B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.36%. Its largest holding is Apogee Therapeutics Inc (APGE), which represents 1.5% of the portfolio. Financial Services is the fund's largest sector exposure at 0.5%.